Peptides like CJC-1295 and GHRP-6 have been studied for their potential to influence growth hormone release. Studies suggest they may synergize when given together, potentially increasing growth hormone production and secretion. This peptide blend studies suggests potential in the context of soft tissue injuries, including those to muscles and ligaments.
Analogous to the naturally occurring peptide ghrelin in its six amino acid structure, the synthetic peptide GHRP-6 is thought to increase the release of growth hormones and aid in maintaining their concentrations by scientists. Scientists speculate it may accomplish this via stimulating GHS-R1a, or the receptor for growth hormone secretagogue. Despite its affinity for the receptors, GHRP-6 seems to be a structurally distinct opioid analog of the peptide Met-enkephalin rather than a homolog of ghrelin.
Although it contains these enkephalins, it does not seem to have the opioid action that has been linked to them. Scientists have placed GHRP-6, a synthetic hexapeptide, in the growth hormone secretagogues (GHSs) family.
CJC-1295, also known as tetra-substituted GRF (1-29), is a peptide analog of natural growth hormone-releasing hormone (GHRH) that is thought to stimulate the production of growth hormone. It is structurally comparable to the first 29 amino acids of GHRH, the shortest chain that might bind to the GHRH receptors. Four modified amino acids from GHRH’s original 29 are responsible for the major structural differences between CJC-1295 and GRF (1-29).
Findings imply that these alterations to the second, eighth, fifteenth, and twenty-seventh amino acids of the peptide may improve its stability in the presence of the proteolytic enzyme dipeptidyl peptidase-4. Specifically, the following are part of the changes:
- D-alanine is substituted with L-alanine at the second position, which is thought to improve the molecule’s stability.
- Changing the eighth position from asparagine to glutamine may decrease asparagine rearrangement and amide hydrolysis.
- Putting alanine instead of glycine at position 15 is thought to increase bioactivity.
- Inhibiting methionine oxidation by replacing it with leucine at position 27.
CJC-1295 and GHRP-6 Peptide Blend: Growth Hormone
Research models were randomly assigned to either a group that got a placebo or received the CJC-1295 peptide. Each subject’s blood was taken before and after exposure to the peptide. Researchers speculated that the peptide may have led to a 7.5-fold rise in the subjects’ growth hormone levels relative to the placebo group based on these data. One week after the peptide was present, the growth hormone levels appeared to have increased gradually and then stabilized.
In a different experimental study, research models were given increasing peptide quantities. All research models were randomly assigned to one of two groups: those given the peptide and those given a placebo. When the blood samples were analyzed after the trial, it seemed that the growth hormone levels had increased by as much as a factor of 10.
Researchers in charge of this experiment said, “The significant enhancement of trough GH levels by constant GHRH stimulation involves the importance of this effect on increasing IGF-I. Long-acting GHRH preparations may help subjects with intact pituitary GH secretory capability.”
Younger test subjects were given GHRP-6 peptide in an experimental study looking at the potential of the peptide. Some subjects were given the peptide, while others were given a combination of the peptide and the growth hormone booster arginine. Findings proposed that growth hormone levels appeared to grow exponentially and similarly in all research models, irrespective of the presence of arginine when the trial was completed.
CJC-1295 and GHRP-6 Peptide Blend: Hypothyroidism
Low growth hormone levels are a hallmark of hypothyroidism. Models of hypothyroidism were given either GHRP-6 peptide, GHRH peptide, or a combination of peptides (such as CJC-1295 and GHRP-6), as suggested by an experimental study conducted in 1997. Subjects given the combination suggested considerably greater levels of growth hormones than those given the separate peptides. Somatostatin, which may suppress growth hormone release, may be an antagonist of the GHRP-6 peptide’s properties. Because of this, the peptide blend looked to be more impactful.
As proposed by research conducted by F R Pimentel-Filho et al., “when GHRP-6 was associated with GHRH, a noteworthy increase in the GH response was observed in these subjects,” which may indicate that somatostatin has a role in this phenomenon. Researchers’ findings implied that thyroid hormones may influence GH’s release in response to GHRH and GHRP-6. Yet further research is required to shed light on this theory.
CJC-1295 and GHRP-6 Peptide Blend and Cells
Injury and multi-organ failure were artificially produced in animal models used in the experiment. The GHRP-6 peptide was given alone or in tandem with epidermal growth factor (EGF). It was suggested in the lab that the peptide may have the potential to impact these animals’ intestinal epithelial cells and increase cellular migration by a factor of three.
Research suggests that GHRP-6 may also exhibit selectivity for CD36 receptors, which may be present on the surface of many different cell types, including adipose (fat) cells, skeletal muscle cells, and immune cells. These receptors may play a role in fat metabolism, serve as a collector receptor for lipids, facilitate their uptake, and even influence immunological responses and inflammation. It’s possible that CD36’s pathways also have a role in controlling angiogenesis, or the process by which new blood vessels develop. Investigations purport that GHRP-6 may enhance cellular healing across various tissues by modulating inflammation and angiogenesis.
Researchers interested in peptide blends for sale may visit the Core Peptides website for the best quality research compound available online.
References
[i] Berlanga-Acosta, Jorge, et al. “Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects.” Clinical Medicine Insights. Cardiology vol. 11 1179546817694558. 2 Mar. 2017, doi:10.1177/1179546817694558. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392015/
[ii] National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 91976842, CJC1295 Without DAC. https://pubchem.ncbi.nlm.nih.gov/compound/CJC1295-Without-DAC.
[iii] National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 9919153, Growth hormone releasing hexapeptide. https://pubchem.ncbi.nlm.nih.gov/compound/9919153.
[iv] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
[v] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
[vi] Bellone J, Ghizzoni L, Amaretti G, Volta C, Boghen MF, Bernasconi S, Ghigo E. Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Eur J Endocrinol. 1995 Oct;133(4):425-9. https://pubmed.ncbi.nlm.nih.gov/7581965/
[vii] Pimentel-Filho FR, Ramos-Dias JC, Ninno FB, Façanha CF, Liberman B, Lengyel AM. Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism. Clin Endocrinol (Oxf). 1997 Mar;46(3):295-300. https://pubmed.ncbi.nlm.nih.gov/9156038/
